BIIB
BIOGEN INC.
$200.05
+0.05%
$29.5B
No data for this timeframe.
Vol
Market Cap$29.5B
Cap SizeLarge Cap
Analyst ConsensusBuy (61%)
Inst. Holders50 funds
Inst. Value$15.2B
Inst. Activity22 buys / 28 sells
Insider Activity1B / 2S
Insider Net $-$665.1K
SEC Reports14
Press Releases10
Congressional1 trades
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000875045·Prev Close $199.96
Recent Activity
Jul 29, 2026
earnings_calendar
BIIB Q2 2026 Earnings After Market Close — 2026-07-29
EPS est: $4.40 | Rev est: $2.4B
Jun 13, 2026
SEC
Piper Sandler double upgrades BIIB to Overweight — PT $214 (+7%)
ANALYST-UPGRADE — Impact 4/10
Jun 9, 2026
Insider
Freire Maria C was granted 2,005 shares
Director
Jun 9, 2026
Insider
Pangalos Menelas N was granted 1,505 shares
Director
Jun 9, 2026
Insider
Minor Lloyd was granted 1,505 shares
Director
Jun 8, 2026
SEC
Needham upgrades BIIB to Buy — PT $255 (+30.5%)
ANALYST-UPGRADE — Impact 2/10
May 22, 2026
Event
TOFIDENCE
Supplemental Approval — TOCILIZUMAB — INJECTABLE — INTRAVENOUS
May 20, 2026
SEC
Wells Fargo double upgrades BIIB to Overweight — PT $250 (+31.2%)
ANALYST-UPGRADE — Impact 3/10
Price Targets
$220.13
+10.0% upside
Buy
Current $200.05
Low $150.00
Median $217.50
High $300.00
30 analysts
$150.00
$300.00
Analyst Ratings
9Strong Buy
18Buy
16Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | Needham | UPGRADE | Hold → Buy |
| May 27, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 15, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| May 1, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Apr 30, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.03 | $-21.10 — $4.26 | -63% YoY | 21 |
| Next Q | $3.91 ▼ -0.9% | $3.20 — $4.66 | -19% YoY | 21 |
| Current FY | $13.26 ▼ -1.0% | $-10.65 — $15.90 | -13% YoY | 23 |
| Next FY | $16.68 ▲ +0.7% | $14.25 — $19.35 | 26% YoY | 23 |
Latest Reports
BULLISH
ANALYST-UPGRADE
4/10
Piper Sandler double upgrades BIIB to Overweight — PT $214 (+7%)
Jun 13, 2026
NEUTRAL
Press
5/10
Biogen and UCB presented Phase 3 PHOENYCS GO data at EULAR 2026 for dapirolizumab pegol (DZP) in systemic lupus erythema
Jun 4, 2026
MIXED
ANALYST-UPGRADE
3/10
Wells Fargo double upgrades BIIB to Overweight — PT $250 (+31.2%)
May 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $2.9B | — |
| FMR LLC | $2.3B | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7B | — |
| STATE STREET CORP | $1.3B | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.2B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Freire Maria | A | $0.00 |
| Jun 9, 2026 | Pangalos Menelas | A | $0.00 |
| Jun 9, 2026 | Minor Lloyd | A | $0.00 |
| Jun 9, 2026 | Pangalos Menelas | M | $0.00 |
| Jun 9, 2026 | Patolawala Monish | A | $0.00 |
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
50 institutional holders with $15.2B total value (83,176,794 shares) as of 2026-Q1. Top holders: BlackRock,, FMR, VANGUARD. Net selling activity: 28 institutions trimmed/exited vs 22 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 15,974,601 | $2.9B | 19.2% | — |
| 2 | FMR LLC | 12,807,541 | $2.3B | 15.4% | ADD +35.9% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 9,537,417 | $1.7B | 11.5% | — |
| 4 | STATE STREET CORP | 7,167,922 | $1.3B | 8.6% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,531,727 | $1.2B | 7.9% | — |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 2,961,641 | $543.0M | 3.6% | — |
| 7 | MORGAN STANLEY | 2,170,940 | $398.0M | 2.6% | — |
| 8 | Invesco Ltd. | 1,745,255 | $320.0M | 2.1% | — |
| 9 | Legal & General Group Plc | 1,349,832 | $247.5M | 1.6% | — |
| 10 | BANK OF AMERICA CORP /DE/ | 1,156,369 | $212.0M | 1.4% | — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,149,394 | $210.7M | 1.4% | — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 1,079,119 | $197.9M | 1.3% | — |
| 13 | DEUTSCHE BANK AG\ | 1,063,828 | $195.0M | 1.3% | — |
| 14 | GOLDMAN SACHS GROUP INC | 1,051,094 | $192.7M | 1.3% | — |
| 15 | Pictet Asset Management Holding SA | 913,328 | $168.3M | 1.1% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 825,531 | $151.3M | 1.0% | — |
| 17 | Point72 Asset Management, L.P. | 809,617 | $148.4M | 1.0% | TRIM -71.2% |
| 18 | Alyeska Investment Group, L.P. | 805,050 | $147.6M | 1.0% | — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 798,700 | $146.4M | 1.0% | — |
| 20 | Amundi | 790,827 | $145.0M | 1.0% | ADD +38.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 9,425,863 | 12,807,541 | +35.9% | $2.3B | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 2,813,192 | 809,617 | -71.2% | $148.4M | 2026-Q1 |
| Amundi | ADD | 572,429 | 790,827 | +38.2% | $145.0M | 2026-Q1 |
| AustralianSuper Pty Ltd | ADD | 476,812 | 616,193 | +29.2% | $113.0M | 2026-Q1 |
| Artemis Investment Management LLP | DOUBLED | 226,845 | 571,571 | +152.0% | $104.8M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 246,650 | 320,785 | +30.1% | $58.8M | 2026-Q1 |
| Swedbank AB | ADD | 231,609 | 289,840 | +25.1% | $53.1M | 2026-Q1 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | TRIM | 521,101 | 280,783 | -46.1% | $51.5M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 385,928 | 229,879 | -40.4% | $42.1M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 399,196 | 203,396 | -49.0% | $37.3M | 2026-Q1 |
| Allianz Asset Management GmbH | TRIM | 247,722 | 178,049 | -28.1% | $32.6M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 353,493 | 163,887 | -53.6% | $30.0M | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEW | — | 151,993 | — | $27.9M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 3,203 | 142,065 | +4335.4% | $26.0M | 2026-Q1 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | ADD | 110,268 | 141,324 | +28.2% | $25.9M | 2026-Q1 |
| LMR Partners LLP | DOUBLED | 8,630 | 116,131 | +1245.7% | $21.3M | 2026-Q1 |
| FEDERATED HERMES, INC. | TRIM | 131,168 | 97,279 | -25.8% | $17.8M | 2026-Q1 |
| Korea Investment CORP | ADD | 53,907 | 73,988 | +37.3% | $13.6M | 2026-Q1 |
| Mariner, LLC | ADD | 52,475 | 72,036 | +37.3% | $13.2M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 123,736 | 68,243 | -44.8% | $12.6M | 2026-Q1 |
| HighTower Advisors, LLC | DOUBLED | 11,959 | 49,851 | +316.8% | $9.1M | 2026-Q1 |
| BANCO BILBAO VIZCAYA ARGENTARIA, S.A. | TRIM | 146,951 | 42,471 | -71.1% | $7.8M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 26,553 | 39,303 | +48.0% | $7.2M | 2026-Q1 |
| State of Tennessee, Department of Treasury | TRIM | 71,467 | 39,265 | -45.1% | $7.2M | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 37,948 | 62,530 | +64.8% | $6.7M | 2026-Q1 |
19 unique insiders with 49 transactions. Net insider value: -$665.1K ($585.11 bought, $665.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Freire Maria C | Director | AWARD | 2,005 | — | — |
| Jun 9, 2026 | Pangalos Menelas N | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Minor Lloyd | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Pangalos Menelas N | Director | EXERCISE | 2,370 | — | — |
| Jun 9, 2026 | Patolawala Monish D | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | LANGER SUSAN | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Mantas Jesus B | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | Rowinsky Eric K | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | SHERWIN STEPHEN A | Director | AWARD | 1,505 | — | — |
| Jun 9, 2026 | HAWKINS WILLIAM A | Director | AWARD | 1,505 | — | — |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | TAX W/H | 455 | $187.06 | $85.1K |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | EXERCISE | 939 | — | — |
| Apr 1, 2026 | Godbout Sean | Chief Accounting Officer | EXERCISE | 181 | — | — |
| Apr 1, 2026 | Godbout Sean | Chief Accounting Officer | TAX W/H | 54 | $183.78 | $9.9K |
| Feb 13, 2026 | Viehbacher Christopher | President and CEO | AWARD | 38,015 | — | — |
| Feb 13, 2026 | Singhal Priya | Head of Development | AWARD | 10,560 | — | — |
| Feb 13, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | AWARD | 10,560 | — | — |
| Feb 13, 2026 | Kramer Robin | Chief Financial Officer | AWARD | 8,450 | — | — |
| Feb 13, 2026 | Keeney Adam | Head of Corporate Development | AWARD | 8,025 | — | — |
| Feb 13, 2026 | Izzar Rachid | Head of Global Product Strat. | AWARD | 7,390 | — | — |
| Feb 13, 2026 | Grogan Jane | Head of Research | AWARD | 8,450 | — | — |
| Feb 13, 2026 | Gregory Ginger | EVP, Human Resources | AWARD | 8,025 | — | — |
| Feb 13, 2026 | Godbout Sean | Chief Accounting Officer | AWARD | 1,800 | — | — |
| Feb 13, 2026 | ALEXANDER SUSAN H | EVP Chief Legal Officer | AWARD | 8,450 | — | — |
| Feb 12, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | BUY | 3 | $195.04 | $585.11 |
| Feb 9, 2026 | Singhal Priya | Head of Development | SELL | 2,660 | $199.83 | $531.5K |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | TAX W/H | 1,017 | $201.18 | $204.6K |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | EXERCISE | 2,102 | — | — |
| Feb 6, 2026 | Singhal Priya | Head of Development | TAX W/H | 1,056 | $201.18 | $212.4K |
| Feb 6, 2026 | Singhal Priya | Head of Development | EXERCISE | 2,217 | — | — |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO | EXERCISE | 9,008 | — | — |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO | TAX W/H | 4,356 | $201.18 | $876.3K |
| Feb 6, 2026 | ALEXANDER SUSAN H | EVP Chief Legal Officer | TAX W/H | 1,059 | $201.18 | $213.0K |
| Feb 6, 2026 | ALEXANDER SUSAN H | EVP Chief Legal Officer | EXERCISE | 2,190 | — | — |
| Feb 6, 2026 | Godbout Sean | Chief Accounting Officer | TAX W/H | 76 | $201.18 | $15.3K |
| Feb 6, 2026 | Godbout Sean | Chief Accounting Officer | EXERCISE | 257 | — | — |
| Feb 6, 2026 | Gregory Ginger | EVP, Human Resources | TAX W/H | 791 | $201.18 | $159.1K |
| Feb 6, 2026 | Gregory Ginger | EVP, Human Resources | EXERCISE | 1,635 | — | — |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | TAX W/H | 805 | $201.18 | $161.9K |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | EXERCISE | 2,044 | — | — |
| Feb 6, 2026 | Grogan Jane | Head of Research | TAX W/H | 407 | $201.18 | $81.9K |
| Feb 6, 2026 | Grogan Jane | Head of Research | EXERCISE | 1,385 | — | — |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | TAX W/H | 589 | $201.18 | $118.5K |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | EXERCISE | 1,802 | — | — |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | TAX W/H | 273 | $201.18 | $54.9K |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | EXERCISE | 789 | — | — |
| Feb 2, 2026 | Singhal Priya | Head of Development | SELL | 748 | $179.30 | $134.1K |
| Jan 30, 2026 | Singhal Priya | Head of Development | EXERCISE | 1,829 | — | — |
| Jan 30, 2026 | Singhal Priya | Head of Development | TAX W/H | 582 | $179.89 | $104.7K |
14 SEC filing reports analyzed. Sentiment: 7 bullish, 0 bearish, 3 mixed, 4 neutral. Avg impact: 3.4/10.
MIXED
ANALYST-UPGRADE
3/10
Wells Fargo double upgrades BIIB to Overweight — PT $250 (+31.2%)
May 20, 2026
BULLISH
ANALYST-UPGRADE
4/10
Piper Sandler double upgrades BIIB to Overweight — PT $214 (+7%)
Jun 13, 2026
BULLISH
ANALYST-UPGRADE
2/10
Needham upgrades BIIB to Buy — PT $255 (+30.5%)
Jun 8, 2026
BULLISH
ANALYST-UPGRADE
4/10
Wells Fargo double upgrades to Overweight with $250 PT — +41% upside
Apr 20, 2026
MIXED
ANALYST-UPGRADE
3/10
UBS double upgrades NVDA to Buy — PT $225 (+21%)
Apr 22, 2026
BULLISH
ANALYST-UPGRADE
3/10
13 firms acted on BIIB: Barclays, HSBC, Freedom Broker, Stifel, Jefferies, Argus Research, Piper Sandler, BMO Capital, Jefferies, Needham, Wolfe Research, Citigroup, Morgan Stanley
May 31, 2026
MIXED
ANALYST-UPGRADE
5/10
Stifel upgrades BIIB to Buy from Hold — PT $202 (+7% implied upside, up from $144)
May 1, 2026
BULLISH
ANALYST-UPGRADE
3/10
UBS upgrades BIIB to Buy — PT $225 (+18.8%)
May 22, 2026
BULLISH
ANALYST-UPGRADE
3/10
Piper Sandler double upgrades NVDA to Overweight — PT $214 (+5%)
May 14, 2026
BULLISH
8-K
7/10
Biogen completed its $5.3B acquisition of Apellis Pharmaceuticals on May 14, 2026, adding commercial
May 14, 2026
NEUTRAL
DEFA14A
2/10
Biogen filed a DEFA14A (additional definitive proxy soliciting materials) providing notice of its 20
Apr 28, 2026
NEUTRAL
8-K
3/10
Biogen issued a preliminary earnings update for Q1 2026, expecting a $34 million charge for acquired
Apr 21, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable
Mar 30, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The filing is an 8-K with
Mar 11, 2026
NEUTRAL
5/10
Biogen and UCB presented Phase 3 PHOENYCS GO data at EULAR 2026 for dapirolizumab pegol (DZP) in sys
Jun 4, 2026
MIXED
5/10
Biogen and UCB announced publication of full Phase 3 PHOENYCS GO results for dapirolizumab pegol (DZ
Jun 1, 2026
BEARISH
7/10
Biogen and Denali announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disea
May 21, 2026
BULLISH
7/10
Biogen completed its acquisition of Apellis Pharmaceuticals for $41 per share in cash plus up to $4
May 14, 2026
MIXED
6/10
Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study m
May 14, 2026
BEARISH
6/10
Biogen and Eisai announced a 3-month FDA review extension for the sBLA of LEQEMBI IQLIK (once-weekly
May 8, 2026
BULLISH
7/10
Biogen has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma, c
Apr 20, 2026
BULLISH
7/10
Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, totaling $5.6
Mar 31, 2026
BULLISH
8/10
Biogen announced positive Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus
Mar 28, 2026
BULLISH
8/10
Biogen announced upcoming presentation of late-breaking Phase 2 (Part A) results from the AMETHYST s
Mar 19, 2026
Current analyst consensus: Buy (61% buy). Based on 44 analysts: 9 strong buy, 18 buy, 16 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$220.13 mean target
+10.0% upside
Buy (1.97)
$150.00 Low
$300.00 High
| Metric | Value |
|---|---|
| Current Price | $200.05 |
| Target Low | $150.00 |
| Target Mean | $220.13 |
| Target Median | $217.50 |
| Target High | $300.00 |
| # Analysts | 30 |
| Recommendation | Buy (1.97) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.03 | $-21.10 | $4.26 | -62.9% | +0.4% | 0↑ 9↓ | $2.4B | -8.4% | 21 |
| Next Q 2026-09-30 |
$3.91 | $3.20 | $4.66 | -18.7% | -0.9% | 2↑ 6↓ | $2.6B | 1.3% | 21 |
| Current FY 2026-12-31 |
$13.26 | $-10.65 | $15.90 | -13.2% | -1.0% | 0↑ 10↓ | $10.0B | 1.6% | 23 |
| Next FY 2027-12-31 |
$16.68 | $14.25 | $19.35 | 25.8% | +0.7% | 8↑ 1↓ | $10.4B | 3.4% | 23 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.031 | |
| 7d ago | $1.940 | +0.091 |
| 30d ago | $2.022 | +0.008 |
| 60d ago | $4.407 | -2.377 |
| 90d ago | $4.321 | -2.291 |
19 analyst firms have rated this stock: 4 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | Needham | UPGRADE | Hold | Buy |
| May 27, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 15, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| May 1, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Apr 30, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 30, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 30, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 22, 2026 | UBS | UPGRADE | Neutral | Buy |
| Apr 20, 2026 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Apr 14, 2026 | Piper Sandler | UPGRADE | Neutral | Overweight |
| Apr 13, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Apr 13, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 1, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 1, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | HSBC | MAINTAIN | Reduce | Reduce |
| Feb 23, 2026 | Freedom Broker | MAINTAIN | Hold | Hold |
| Feb 20, 2026 | Barclays | INITIATE | — | Equal-Weight |
| Feb 10, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Feb 9, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Feb 9, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | BMO Capital | MAINTAIN | Market Perform | Market Perform |
| Feb 9, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 9, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 9, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 9, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Feb 9, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Feb 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Jan 30, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 27, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Jan 7, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 18 | 16 | 1 | 0 | 61% | |
| May 1, 2026 | 9 | 15 | 18 | 1 | 0 | 56% | |
| Apr 1, 2026 | 9 | 11 | 22 | 1 | 0 | 47% | |
| Mar 1, 2026 | 9 | 11 | 22 | 1 | 0 | 47% | |
| Feb 1, 2026 | 9 | 11 | 21 | 1 | 0 | 48% | |
| Jan 1, 2026 | 9 | 11 | 21 | 1 | 0 | 48% | |
| Dec 1, 2025 | 9 | 12 | 21 | 0 | 0 | 50% | |
| Nov 1, 2025 | 8 | 13 | 21 | 0 | 0 | 50% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Biogen Inc | Feb 16, 2026 (18d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jul 29, 2026
earnings_calendar
BIIB Q2 2026 Earnings After Market Close — 2026-07-29
EPS est: $4.40 | Rev est: $2.4B
Jun 4, 2026
other
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
<p>CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- <strong> </strong> <a href="https://www.globenewswire.com/Tracker?data=hPxI_mCodj0_aUCNuVm35c
Jun 4, 2026
fda
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
<p>BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=c5d6616oC1bYwKRGubo
Jun 3, 2026
other
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
<p>CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6vkOQ5eV6ztnTE8P3MutS58MQVNu8VOgRO1a2AZE8
Jun 1, 2026
contract
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
<p>BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=P5fkXjrpMQ61BSApsTM
May 29, 2026
Clinical Trial
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Phase Phase 2 — COMPLETED
May 29, 2026
clinical_trial_readout
Results Pending: BIIB122 (Phase 2) — Completed 81d ago
Trial: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Betwe
May 25, 2026
dark_pool
Dark Pool: BIIB — 0.9M shares, 31,974 trades
Week starting 2026-05-25. Total ATS volume: 942,726 shares across 31,974 trades.
May 24, 2026
fda_pdufa
PDUFA: BIIB — LEQEMBI in IQLIK subcutaneous treatment — 2026-05-24
FDA target action date 2026-05-24 for BIIB (BIOGEN INC.). Drug: LEQEMBI. Indication: IQLIK subcutaneous treatment. FDA Priority Review granted for LEQ
May 22, 2026
FDA
TOFIDENCE
Supplemental Approval — TOCILIZUMAB — INJECTABLE — INTRAVENOUS
May 21, 2026
contract
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
<p>CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=aRNdAkEZs
May 20, 2026
Clinical Trial
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Phase Phase 3 — COMPLETED
May 18, 2026
dark_pool
Dark Pool: BIIB — 1.5M shares, 42,814 trades
Week starting 2026-05-18. Total ATS volume: 1,461,646 shares across 42,814 trades.
May 14, 2026
m_and_a
Biogen Completes Acquisition of Apellis Pharmaceuticals
<p align="justify">CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W-OIuvVUjGbgwnZXAl5pS5rNIq
May 14, 2026
fda
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance dir
May 14, 2026
short_volume
Short Volume: BIIB — 66.8% short (0.8M / 1.2M)
Short: 822,048 | Exempt: 1,075 | TRF Vol: 1,230,815 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: BIIB — 65.8% short (0.4M / 0.6M)
Short: 366,010 | Exempt: 0 | TRF Vol: 555,948 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: BIIB — 2.6M shares, 52,812 trades
Week starting 2026-05-11. Total ATS volume: 2,575,000 shares across 52,812 trades.
May 4, 2026
Clinical Trial
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 1, 2026
Clinical Trial
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
Phase Phase 2 — COMPLETED
Apr 29, 2026
Clinical Trial
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Phase Phase 2 — COMPLETED
Mar 30, 2026
Enforcement
1:25-cv-11680 Walgreen Co. et al v. Biogen, Inc.
Court ruling from United States District Court for the Northern District of Illinois. Docket: N/A
Dec 20, 2024
FDA
SKYCLARYS
Supplemental Approval — Efficacy — OMAVELOXOLONE — CAPSULE — ORAL
Jul 31, 2024
FDA
ZURZUVAE
Supplemental Approval — Labeling — ZURANOLONE — CAPSULE — ORAL